Swipe tables sideways to see all columns.
Research findings
Comparative structure study
The largest recorded chain role, Biomedicine and medical devices / Complete systems and use-case applications, contains 121 records (76.6% of this 158-record cohort). Companies may carry multiple labels in this dimension; participation rates are not additive market shares.
The recorded sub-industry label Advanced medical devices accounts for 42.4% here (67/158), compared with 35.4% in the parent set (609/1,721), an absolute gap of 7.0 percentage points.
31/158 companies link to pages with existing source-supported excerpts (19.6% of the cohort). The other 127 records remain usable for archive composition, but do not support new operating case studies.
| Company cohort | Directly linked pages | Share of public archive | Archive date |
|---|---|---|---|
| 158 | 158 | 0.8% | 2026-10-16 |
An ID-deduplicated archive snapshot, not the whole market, current recognition or operating results.
Comparable sets and compositional differences
The parent set, Biomedicine, contains 1,721 records. This cohort contributes 158 (9.2%); 1,563 records remain after excluding it.
The parent set, Zhejiang, contains 1,840 records. This cohort contributes 158 (8.6%); 1,682 records remain after excluding it.
| Category | Cohort count/base | Reference: Biomedicine | Gap (pp) | Representation ratio | Rest count/base |
|---|---|---|---|---|---|
| sub-industry · Advanced medical devices | 67/158 · 42.4% | 609/1,721 · 35.4% | +7.0 | 1.20 | 542/1,563 |
| sub-industry · Biomedicine | 51/158 · 32.3% | 667/1,721 · 38.8% | -6.5 | 0.83 | 616/1,563 |
| chain role · Advanced equipment and industrial automation / Process equipment and inspection instruments | 25/158 · 15.8% | 223/1,721 · 13.0% | +2.9 | 1.22 | 198/1,563 |
| sub-industry · Chemical drugs and formulations | 16/158 · 10.1% | 143/1,721 · 8.3% | +1.8 | 1.22 | 127/1,563 |
| chain role · New energy and power equipment / Complete systems and use-case applications | 5/158 · 3.2% | 25/1,721 · 1.5% | +1.7 | 2.18 | 20/1,563 |
| chain role · Biomedicine and medical devices / Complete systems and use-case applications | 121/158 · 76.6% | 1,292/1,721 · 75.1% | +1.5 | 1.02 | 1,171/1,563 |
Ratio of label participation, not market share; multi-label counts overlap.
Excluding this cohort, the recorded sub-industry label Advanced medical devices covers 542/1,563 remaining records (34.7%), an absolute gap of 7.7 percentage points from this cohort.
Concentration and cross-sectional structure
| Recorded label | Records | Share of cohort |
|---|---|---|
| Biomedicine and medical devices / Complete systems and use-case applications | 121 | 76.6% |
| Advanced equipment and industrial automation / Process equipment and inspection instruments | 25 | 15.8% |
| New energy and power equipment / Complete systems and use-case applications | 5 | 3.2% |
| Fine chemicals / Basic and process materials | 3 | 1.9% |
| Energy conservation, environmental protection and resource recycling / Complete systems and use-case applications | 2 | 1.3% |
| Biomedicine and medical devices / Digital software and industrial services | 1 | 0.6% |
| Electronic information and digital technology / Complete systems and use-case applications | 1 | 0.6% |
Record counts do not rank supply capability or economic size.
Evidence coverage and strength of conclusions
| Record field | Non-empty/cohort | Completion |
|---|---|---|
| Company name | 158/158 | 100.0% |
| reporting jurisdiction | 158/158 | 100.0% |
| industry | 158/158 | 100.0% |
| Recorded products | 158/158 | 100.0% |
| sub-industry | 158/158 | 100.0% |
| Chain labels | 158/158 | 100.0% |
Non-empty fields are not necessarily accurate or supported by originals.
| Scope of source support | Count |
|---|---|
| Profiles with source-supported excerpts | 31 |
| Distinct corresponding companies | 31 |
| Reviewed Chinese/English paragraph pairs | 33 |
Counts concern existing reviewed bilingual excerpts, not re-certification of originals or entire reports.
| Transparent rule reminder | Records | Cohort share |
|---|---|---|
| Contains registration-narrative wording | 1 | 0.6% |
| Only generic operations vocabulary remains | 4 | 2.5% |
A rule hit prioritises review; it does not establish that the entire field is wrong. One record can trigger several rules.
Intersection with 2026 local lists
35 of this cohort’s 158 records link through existing company-ID mappings to 2026 lists from all jurisdictions (22.2%). This intersection measures list linkage, not successful recognition or company growth.
| Observation set | List records | New-applicant records | Review records | Mapped company IDs |
|---|---|---|---|---|
| National list records linked to this cohort’s IDs | 35 | 2 | 33 | 35 |
List rows and company IDs are separate counts, not new firms or final recognition.
Stored 2026 local-recommendation records, sources and stage definitionsRelated provincial study
The 2025 macro context for Zhejiang uses a different denominator from this cohort.
Zhejiang Company Archive StudyRecorded roles and delivery checks
Drug-production leads need validation and change records
The Chemical drugs and formulations label covers 16 records (10.1% of this cohort). This archive clue raises a verification question about Defined pharmaceutical-production or testing services with quality documents; it does not establish that these companies already deliver it.
Delivery framework, stages and original sourcesRelated studies and shared records
Shared records with Zhejiang / Biomedicine and medical devices / Complete systems and use-case applications Company Structure Study: 121; records in this cohort but outside that set: 37. The intersection/union ratio is 74.2%, a measure of label overlap rather than business collaboration. Read comparison
Shared records with Biomedicine / Biomedicine and medical devices / Complete systems and use-case applications Supply-chain Study: 121; records in this cohort but outside that set: 37. The intersection/union ratio is 9.1%, a measure of label overlap rather than business collaboration. Read comparison
Company samples and record links
| Company | Jurisdiction | Recorded industry |
|---|---|---|
| Zhejiang Fangyuanlixin Vacuum Equipment Co., Ltd. | Zhejiang | Biomedicine |
| Hangzhou Bosheng Medical Laboratory Co., Ltd. | Zhejiang | Biomedicine |
| Hangzhou Kangji Medical Instrument Co., Ltd. | Zhejiang | Biomedicine |
| Zhejiang Haisen Pharmaceutical Co., Ltd. | Zhejiang | Biomedicine |
| Jitai Technology (Beijing) Co., Ltd. | Zhejiang | Biomedicine |
| Hangzhou Ruijian Medical Group Co., Ltd. | Zhejiang | Biomedicine |
| Zhejiang Xunshi Technology Co., Ltd. | Zhejiang | Biomedicine |
| Hangzhou Bori Technology Co., Ltd. | Zhejiang | Biomedicine |
Stable-ID samples, not rankings; metrics use the full cohort.
Directly related profiles and reports
| Page | Presentation |
|---|---|
| Zhejiang Fangyuanlixin Vacuum Equipment Co., Ltd. | Company data profile |
| Hangzhou Bosheng Medical Laboratory Co., Ltd. | Company report page |
| Hangzhou Kangji Medical Instrument Co., Ltd. | Company report page |
| Zhejiang Haisen Pharmaceutical Co., Ltd. | Company data profile |
| Jitai Technology (Beijing) Co., Ltd. | Company data profile |
| Hangzhou Ruijian Medical Group Co., Ltd. | Company data profile |